Jan 30, 2026 07:00AM
Jan 30, 2026 07:00AM
Jan 30, 2026 07:00AM
Jan 27, 2025 07:14AM
Oct 21, 2024 09:56AM
Oct 7, 2024 07:00AM
Aug 9, 2024 09:00AM The Galien Foundation Announces 2024 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"
May 29, 2024 07:03AM
May 29, 2024 07:00AM
Feb 1, 2024 09:00AM
Nov 7, 2023 07:00AM
Aug 10, 2023 07:00AM
Jul 27, 2023 09:15AM
Apr 24, 2023 04:47PM Ideaya Biosciences upgraded to Buy, Shares jump on positive Interim Phase 2 data for Darovasertib and Crizotinib combination
Mar 1, 2023 07:00AM
Mar 1, 2023 07:00AM
Dec 15, 2022 06:00AM
Dec 15, 2022 06:00AM
Nov 9, 2022 08:00AM
Aug 11, 2022 08:00AM
Aug 10, 2022 07:00AM Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 10, 2022 07:00AM
Aug 3, 2022 07:00AM
Aug 3, 2022 07:00AM
Jul 11, 2022 07:00AM
Jul 11, 2022 07:00AM
Jun 27, 2022 05:59AM
Jun 25, 2022 04:00AM Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
Jun 25, 2022 04:00AM
Jun 15, 2022 07:00AM
Jun 8, 2022 07:03AM
Jun 8, 2022 07:00AM
Jun 8, 2022 07:00AM
Jun 6, 2022 07:04AM
Jun 6, 2022 07:00AM Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 6, 2022 07:00AM
Jun 3, 2022 07:01AM
Jun 3, 2022 07:00AM
Jun 3, 2022 07:00AM
Jun 1, 2022 04:30PM
Jun 1, 2022 04:30PM
May 26, 2022 06:00PM Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 06:00PM
May 23, 2022 07:26AM
May 23, 2022 07:24AM
May 12, 2022 09:17AM
May 12, 2022 08:00AM
May 11, 2022 07:00AM
May 11, 2022 07:00AM Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 7, 2022 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All